A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma.

Trial Profile

A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Actual end date changed from Mar 2010 to Dec 2008 as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Results presented at ASCO 2010 (abstract no. 8578), according to an Abraxis BioScience media release.
    • 10 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top